Augusto B Federici Selected Research

von Willebrand Factor

8/2022	Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis: An expert opinion paper from an Italian panel.
1/2022	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
10/2021	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.
1/2020	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
1/2018	Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.
7/2016	Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
6/2014	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.
3/2013	Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
9/2012	Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients.
1/2012	Current management of patients with severe von Willebrand disease type 3: a 2012 update.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Augusto B Federici Research Topics

Disease

39	Hemorrhage 01/2022 - 02/2002
26	von Willebrand Diseases (von Willebrand's Disease) 08/2022 - 02/2002
9	Hemophilia A (Haemophilia) 01/2019 - 04/2005
8	Type 3 von Willebrand Disease 01/2022 - 05/2003
6	Type 1 von Willebrand Disease 03/2013 - 01/2007
4	Menorrhagia 01/2020 - 07/2009
4	Thrombocytopenia (Thrombopenia) 07/2016 - 01/2009
3	Neoplasms (Cancer) 01/2019 - 04/2012
3	Thrombosis (Thrombus) 01/2019 - 02/2016
3	Type 2 von Willebrand Disease 07/2016 - 03/2004
2	Infections 12/2020 - 04/2006
2	Epistaxis (Nosebleed) 01/2020 - 09/2013
1	Headache (Headaches) 12/2020
1	Dizziness (Lightheadedness) 12/2020
1	Hypesthesia (Numbness) 12/2020
1	Essential Thrombocythemia 12/2020
1	Melanoma (Melanoma, Malignant) 12/2020
1	Polycythemia Vera 12/2020
1	Primary Myelofibrosis (Myelosclerosis) 12/2020
1	Skin Neoplasms (Skin Cancer) 12/2020
1	Hemarthrosis 01/2020
1	Venous Thromboembolism 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Atherosclerosis 02/2016
1	Vitamin K Deficiency 05/2014
1	Disseminated Intravascular Coagulation 05/2014
1	Hepatic Insufficiency 05/2014
1	Anemia 09/2013
1	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2012
1	Hypothyroidism 02/2011
1	Cushing Syndrome 01/2011
1	Pituitary ACTH Hypersecretion 01/2011
1	Paraproteinemias (Monoclonal Gammopathy) 04/2005
1	Vascular System Injuries 01/2003

Drug/Important Bio-Agent (IBA)

39	von Willebrand FactorIBA 08/2022 - 02/2002
17	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 06/2014 - 02/2002
11	Factor VIII (Coagulation Factor VIII)IBA 08/2022 - 03/2004
5	von Willebrand factor drug combination factor VIIIIBA 01/2022 - 03/2003
5	Biomarkers (Surrogate Marker)IBA 03/2013 - 01/2007
3	AntigensIBA 01/2020 - 01/2012
3	Intravenous Immunoglobulins (IVIG)FDA Link 01/2006 - 03/2003
2	Hemostatics (Antihemorrhagics)IBA 01/2020 - 05/2014
2	AnticoagulantsIBA 01/2019 - 05/2014
2	RistocetinIBA 07/2016 - 01/2004
2	Blood Group Antigens (Blood Groups)IBA 04/2011 - 09/2003
2	Biological ProductsIBA 04/2008 - 03/2004
1	ruxolitinibIBA 12/2020
1	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2020
1	Prothrombin (Factor II)IBA 01/2019
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 02/2016
1	AntibodiesIBA 05/2014
1	Dacarbazine (DIC)FDA LinkGeneric 05/2014
1	Hemoglobins (Hemoglobin)IBA 09/2013
1	Recombinant ProteinsIBA 09/2012
1	Messenger RNA (mRNA)IBA 09/2012
1	Oxygen (Dioxygen)IBA 04/2012
1	Tranexamic Acid (AMCA)FDA Link 04/2011
1	Combined Oral ContraceptivesIBA 04/2011
1	IronIBA 04/2011
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 02/2011
1	Vasopressins (Vasopressin)IBA 01/2011
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2011
1	Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)IBA 01/2009
1	Arginine Vasopressin (Argipressin)IBA 05/2008
1	Transaminases (Aminotransferases)IBA 04/2006
1	Antiviral Agents (Antivirals)IBA 04/2006
1	human F8 protein FDA Link 04/2005
1	Immunoglobulins (Immunoglobulin)IBA 04/2005
1	Immunoglobulin G (IgG)IBA 04/2005
1	AutoantibodiesIBA 04/2005
1	CoagulantsIBA 03/2004
1	Proteins (Proteins, Gene)FDA Link 01/2003

Therapy/Procedure

11	Therapeutics 01/2019 - 04/2006
2	Drug Therapy (Chemotherapy) 11/2016 - 05/2014
2	Blood Transfusion (Blood Transfusions) 04/2012 - 09/2008
1	Tooth Extraction (Tooth Extractions) 01/2020
1	Platelet Transfusion (Blood Platelet Transfusions) 11/2016
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/2016
1	Stem Cell Transplantation 11/2016
1	Massage (Zone Therapy) 07/2014
1	Immunomodulation 04/2012
1	Contraindications 07/2007